Viking Therapeutics, Inc. (VKTX) Stock

Viking Therapeutics, Inc. (VKTX) is a Healthcare stock trading at $30.41 (as of 2026-06-18), with a market capitalization of $3.45B and a trailing P/E of -7.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oral therapies for metabolic and endocrine disorders. Its pipeline includes VK2809 for biopsy-confirmed non-alcoholic steatohepatitis and NAFLD, VK5211 for patients recovering from non-elective hip fracture surgery, VK0612 for type 2 diabetes, and VK0214 for X-linked adrenoleukodystrophy.

Valuation — source: SEC EDGAR (first-party)
Price$30.41
Market Cap$3.45B
P/E Ratio-7.2
Price / Book6.87
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Return on Equity-94.1%
Current Ratio5.72
Valuation vs Sector & Industry
Stock P/E-7.2
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-134.1%
vs Industry-141.4%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($351.25M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOBrian Lian
Employees45
CountryUS
IPO Date2015-04-28

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by revenue (market cap unavailable); US-domiciled)

  • Alnylam Pharmaceuticals, Inc. (ALNY)
  • Viatris Inc. (VTRS)
  • Elanco Animal Health Incorporated (ELAN)
  • Jazz Pharmaceuticals plc (JAZZ)
  • Bausch Health Companies Inc. (BHC)
  • Perrigo Company plc (PRGO)
  • Organon & Co. (OGN)
  • Universe Pharmaceuticals Inc. (UPC)
VKTX earnings history · VKTX institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.